Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-10-14 Purchase | 2026-10-16 8:42 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 71,065 | $1.9162 | $136,178 | 2,944,354 (Indirect) | View |
| 2026-10-08 Purchase | 2026-10-13 5:45 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 14,632 | $2.0286 | $29,683 | 2,873,289 (Indirect) | View |
| 2026-10-01 Purchase | 2026-10-05 6:46 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 60,490 | $2.0469 | $123,819 | 2,858,657 (Indirect) | View |
| 2026-09-29 Purchase | 2026-10-01 4:30 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 7,849 | $2.09 | $16,404 | 2,798,167 (Indirect) | View |
| 2026-09-21 Purchase(A) | 2026-10-01 4:05 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 15,089 | $2.1 | $31,687 | 2,790,318 (Indirect) | View |
| 2026-09-21 Purchase | 2026-09-23 6:19 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 15,089 | $2.1 | $31,687 | 2,855,318 (Indirect) | View |
| 2026-09-08 Purchase | 2026-09-10 4:05 pm | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 15,229 | $2.0944 | $31,896 | 2,775,229 (Indirect) | View |
| 2026-09-09 Purchase | 2026-09-10 07:30 am | Grace Therapeutics Inc. | GRCE | Kohli Prashant Chief Executive Officer | 100,000 | $2.14 | $214,000 | 121,357 (Direct) | View |
| 2026-08-14 Purchase | 2026-08-19 07:44 am | Grace Therapeutics Inc. | GRCE | Opaleye Management Inc. 10% Owner | 11,608 | $2.0853 | $24,206 | 2,760,000 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-09-17 Option Award | 2026-09-21 4:22 pm | N/A 2036-09-16 | Grace Therapeutics Inc. | GRCE | NEUGEBOREN EDWARD Director | 12,200 | $0 | 12,200 (Direct) | View |
| 2026-09-17 Option Award | 2026-09-21 4:20 pm | N/A 2036-09-16 | Grace Therapeutics Inc. | GRCE | DAVIS A BRIAN Director | 12,200 | $0 | 12,200 (Direct) | View |
| 2026-09-17 Option Award | 2026-09-21 4:15 pm | N/A 2036-09-16 | Grace Therapeutics Inc. | GRCE | Kavuru Vimal Director | 12,200 | $0 | 12,200 (Direct) | View |
| 2026-09-17 Option Award | 2026-09-21 4:13 pm | N/A 2036-09-16 | Grace Therapeutics Inc. | GRCE | Kottayil George Director | 12,200 | $0 | 12,200 (Direct) | View |
| 2026-08-28 Option Award | 2026-09-01 4:05 pm | N/A 2036-08-27 | Grace Therapeutics Inc. | GRCE | Kumar Amresh VP Program Management | 35,760 | $0 | 35,760 (Direct) | View |
| 2026-08-28 Option Award | 2026-09-01 4:05 pm | N/A 2036-08-27 | Grace Therapeutics Inc. | GRCE | Kohli Prashant Chief Executive Officer | 267,160 | $0 | 267,160 (Direct) | View |
| 2026-08-28 Option Award | 2026-09-01 4:05 pm | N/A 2036-08-27 | Grace Therapeutics Inc. | GRCE | Macdonald R. Loch Chief Medical Officer | 54,690 | $0 | 54,690 (Direct) | View |
| 2026-08-28 Option Award | 2026-09-01 4:05 pm | N/A 2036-08-27 | Grace Therapeutics Inc. | GRCE | DelAversano Robert J Principal Financial Officer | 33,660 | $0 | 33,660 (Direct) | View |
| 2026-01-08 Option Award | 2026-01-12 4:01 pm | N/A 2036-01-08 | Grace Therapeutics Inc. | GRCE | Kavuru Vimal Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2026-01-08 Option Award | 2026-01-12 4:01 pm | N/A 2036-01-08 | Grace Therapeutics Inc. | GRCE | Kottayil George Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2026-01-08 Option Award | 2026-01-12 4:01 pm | N/A 2036-01-08 | Grace Therapeutics Inc. | GRCE | NEUGEBOREN EDWARD Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2026-01-08 Option Award | 2026-01-12 4:01 pm | N/A 2036-01-08 | Grace Therapeutics Inc. | GRCE | DAVIS A BRIAN Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2025-05-09 Option Award | 2025-05-13 5:21 pm | N/A 2035-05-09 | Grace Therapeutics Inc. | GRCE | Kottayil George Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2025-05-09 Option Award | 2025-05-13 5:21 pm | N/A 2035-05-09 | Grace Therapeutics Inc. | GRCE | NEUGEBOREN EDWARD Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2025-05-09 Option Award | 2025-05-13 5:21 pm | N/A 2035-05-09 | Grace Therapeutics Inc. | GRCE | DAVIS A BRIAN Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2025-05-09 Option Award | 2025-05-13 5:21 pm | N/A 2035-05-09 | Grace Therapeutics Inc. | GRCE | Kavuru Vimal Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2025-04-14 Option Award | 2025-04-16 8:58 pm | N/A 2035-04-14 | Grace Therapeutics Inc. | GRCE | Kumar Amresh VP Program Management | 30,000 | $0 | 30,000 (Direct) | View |
| 2025-04-14 Option Award | 2025-04-16 8:58 pm | N/A 2035-04-14 | Grace Therapeutics Inc. | GRCE | Macdonald R. Loch Chief Medical Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2025-04-14 Option Award | 2025-04-16 8:58 pm | N/A 2035-04-14 | Grace Therapeutics Inc. | GRCE | DelAversano Robert J Principal Financial Officer | 20,130 | $0 | 20,130 (Direct) | View |
| 2025-04-14 Option Award | 2025-04-16 8:58 pm | N/A 2035-04-14 | Grace Therapeutics Inc. | GRCE | Kohli Prashant Chief Executive Officer | 225,400 | $0 | 225,400 (Direct) | View |
| 2025-04-14 Option Award | 2025-04-16 8:58 pm | N/A 2035-04-14 | Grace Therapeutics Inc. | GRCE | D'Andrea Carrie VP Clinical Operations | 30,000 | $0 | 30,000 (Direct) | View |
Ownership(A) | 2024-07-11 11:16 am | N/A N/A | Acasti Pharma Inc. | ACST | ADAR1 Capital Management LLC ADAR1 Partners LP 10% Owner | 0 | $0 | 3,141,397 (Indirect) | View |
Ownership | 2024-07-09 8:29 pm | N/A N/A | Acasti Pharma Inc. | ACST | ADAR1 Capital Management LLC ADAR1 Partners LP 10% Owner | 0 | $0 | 959,571 (Indirect) | View |
| 2024-05-06 Option Award(A) | 2024-05-10 4:11 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | D'Andrea Carrie VP Clinical Operations | 19,740 | $0 | 19,740 (Direct) | View |
| 2024-05-06 Option Award(A) | 2024-05-10 4:07 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | Kumar Amresh VP Program Management | 19,740 | $0 | 19,740 (Direct) | View |
| 2024-05-06 Option Award | 2024-05-08 7:19 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | D'Andrea Carrie VP Program Management | 19,740 | $0 | 19,740 (Direct) | View |
| 2024-05-06 Option Award | 2024-05-08 7:19 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | Kumar Amresh VP Clinical Operations | 19,740 | $0 | 19,740 (Direct) | View |
| 2024-05-06 Option Award | 2024-05-08 7:19 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | Macdonald R. Loch Chief Medical Officer | 25,380 | $0 | 25,380 (Direct) | View |
| 2024-05-06 Option Award | 2024-05-08 7:18 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | DelAversano Robert J Principal Financial Officer | 4,500 | $0 | 4,500 (Direct) | View |
| 2024-05-06 Option Award | 2024-05-08 7:18 pm | N/A 2034-05-06 | Acasti Pharma Inc. | ACST | Kohli Prashant Chief Executive Officer | 128,770 | $0 | 128,770 (Direct) | View |
Ownership | 2024-01-08 08:00 am | N/A 2033-12-19 | Acasti Pharma Inc. | ACST | DelAversano Robert J Vice President, Finance | 0 | $0 | 42,000 (Direct) | View |